Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-12-12
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 320
- Registration Number
- NCT00002320
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸Nicholaos Bellos, Dallas, Texas, United States
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00002389
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Kraus Med Partners, Los Angeles, California, United States
🇺🇸Univ of Miami Dept of Medicine, Miami, Florida, United States
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Target Recruit Count
- 160
- Registration Number
- NCT00002401
- Locations
- 🇺🇸
Pharmacia & Upjohn, Peapack, New Jersey, United States
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00002386
- Locations
- 🇺🇸
Riley Hosp for Children, Indianapolis, Indiana, United States
🇺🇸Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT00002430
- Locations
- 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸Tower ID Med Associates, Los Angeles, California, United States
🇺🇸AIDS Community Research Consortium, Redwood City, California, United States
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 186
- Registration Number
- NCT00002424
- Locations
- 🇺🇸
UCLA School of Medicine / Ctr for Research and Education, Los Angeles, California, United States
🇺🇸Associates in Research, Fort Myers, Florida, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 32
- Registration Number
- NCT00000865
- Locations
- 🇺🇸
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-05-15
- Target Recruit Count
- 25
- Registration Number
- NCT00006617
- Locations
- 🇺🇸
Aaron Diamond AIDS Res Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.